128 related articles for article (PubMed ID: 12352597)
1. 111In-pentetreotide versus bone scintigraphy in the detection of bony metastases of neuroblastoma.
Juweid ME; Menda Y; O'Dorisio MS; Bushnell D; Blake M; Madsen M; Johnson J; Graham MM
Nucl Med Commun; 2002 Oct; 23(10):983-9. PubMed ID: 12352597
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
3. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
5. The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer.
Prior JO; Barghouth G; Delaloye JF; Leyvraz S; Bischof Delaloye A
Nucl Med Commun; 2003 Jan; 24(1):29-36. PubMed ID: 12501017
[TBL] [Abstract][Full Text] [Related]
6. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
[TBL] [Abstract][Full Text] [Related]
7. The role of 99Tcm-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma: comparison with 131I-MIBG and 99Tcm-MDP scintigraphy.
Burak Z; Yüksel DA; Cetingül N; Kantar M; Ozkiliç H; Moretti JL
Nucl Med Commun; 1999 Nov; 20(11):991-1000. PubMed ID: 10572908
[TBL] [Abstract][Full Text] [Related]
8. Bone scans in neuroblastoma.
Bhogate BM; Samuel AM; Ramanathan P
Indian J Cancer; 1993 Mar; 30(1):5-9. PubMed ID: 8500809
[TBL] [Abstract][Full Text] [Related]
9. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy.
Choi YJ; Hwang HS; Kim HJ; Jeong YH; Cho A; Lee JH; Yun M; Lee JD; Kang WJ
Ann Nucl Med; 2014 May; 28(4):304-13. PubMed ID: 24481823
[TBL] [Abstract][Full Text] [Related]
10. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
11. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.
Shulkin BL; Shapiro B; Hutchinson RJ
J Nucl Med; 1992 Oct; 33(10):1735-40. PubMed ID: 1403138
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
13. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of morphological/immunohistochemical versus nuclear medicine imaging modalities in detecting metastatic bone and/or marrow deposits in neuroblastoma patients.
Zaher Ael-S; Zaher AM; Moneer MM; El Gamal BM
J Egypt Natl Canc Inst; 2011 Jun; 23(2):79-88. PubMed ID: 22099965
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the utility of
Gauguet JM; Pace-Emerson T; Grant FD; Shusterman S; DuBois SG; Frazier AL; Voss SD
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449267
[TBL] [Abstract][Full Text] [Related]
16. Does I-131-MIBG underestimate skeletal disease burden in neuroblastoma?
Barai S; Bandopadhayaya GP; Malhotra A; Agarwal S; Kumar R; Dhanapathi H
J Postgrad Med; 2004; 50(4):257-60; discussion 260-1. PubMed ID: 15623965
[TBL] [Abstract][Full Text] [Related]
17. [The place of 99mTc-MDP skeletal scintigraphy in neuroblastoma. Is a new assessment necessary?].
Sautter-Bihl ML; Bihl H; Heinze HG
Nuklearmedizin; 1991 Feb; 30(1):7-12. PubMed ID: 2062676
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma.
Perel Y; Conway J; Kletzel M; Goldman J; Weiss S; Feyler A; Cohn SL
J Pediatr Hematol Oncol; 1999; 21(1):13-8. PubMed ID: 10029806
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract.
Kim MR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2008 Feb; 44(2):148-52. PubMed ID: 17350879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
